Petauri

Heading to ESMO - European Society for Medical Oncology's annual meeting? Bluprint Oncology, Mtech Access, and Petauri Evidence will be there! Reach out to [email protected] or send a message to Nicole Lodowski, Christopher Leidli, and Blaire Hannon to schedule a time to meet. Let’s connect and explore how we can make a difference—together. To learn more about how Petauri™ is speeding access to life-changing healthcare innovations, visit our website https://petauri.com/ #ESMO24 #oncology #marketaccess #evidence #scientificcommunications #healthcareinnovation

Petauri™ is dedicated to advancing healthcare through real-world evidence (RWE) and supporting innovation, which can involve integrating real-world data (RWD), such as electronic health records, medical claims, and patient-generated data, into regulatory decision-making across the lifecycle. The FDA’s recent 2024 guidance on RWD in regulatory decision-making marks a significant milestone for the healthcare industry. RWD can enhance the approval process for new drugs and devices and support post-market surveillance, health policy formation, and play a critical role in improving patient outcomes. The FDA's full guidance can be found at https://lnkd.in/dKVdGySM. To have a strategic discussion around how RWD can be used to support your product’s value across the lifecycle, please contact us at https://lnkd.in/eadTaaSM #HealthcareInnovation #RealWorldData #RealWordEvidence #Healthcare #HEOR #MarketAccess #RWD #RWE #PatientOutcomes #MedicalResearch

At Petauri™, we're tackling the complexities of specialty care by removing barriers and breaking down silos, just as highlighted by Ryan Nix from Vanderbilt Specialty Pharmacy. Specialty care often faces hurdles that prevent patients from starting or staying on therapy. By embracing a collaborative approach and integrating care across all touchpoints, Petauri is helping to streamline patient experiences and improve outcomes. Our commitment is clear: to speed healthcare innovations to the patients who need them most. To learn more about our strategies and how we can enhance your specialty care programs, contact us at https://lnkd.in/ebCSBH8b #Healthcare #HealthcareInnovation #PatientCare #HealthEquity

We're excited to announce that Petauri™ now boasts a team of over 360 talented professionals, all dedicated to speeding healthcare innovations to the patients who need them. As we continue to expand and innovate, we're committed to driving positive change and making an impact in the healthcare landscape. Want to learn more about our rapid growth trajectory and how we're making a difference? Contact us at https://lnkd.in/ebCSBH8b #Healthcare #MarketAccess #MedicalAffairs #HealthcareTransformation

In the wake of the Maximum Fair Prices (MFPs) announced in the Drug Price Negotiation Program (DPNP) published by the Centers for Medicare and Medicaid Services (CMS), we believe that a forward-thinking value strategy––encompassing price and target indications––is crucial. Companies need to establish the distinct value of their therapies at launch, bearing in mind the potential impact of the IRA throughout the drug's lifecycle. This involves anticipating how pricing negotiations might affect the market basket and emerging pipeline products, thus requiring thoughtful planning and scenario forecasting.    Read our full commentary at https://lnkd.in/gW_54SMp and contact us at https://lnkd.in/ebCSBH8b to discuss further.   #Healthcare #MarketAccess #CMS #HEOR #RWE 

Yesterday, the Centers for Medicare and Medicaid Services (CMS) published the Maximum Fair Prices (MFPs) for the first 10 drugs under the Drug Price Negotiation Program (DPNP). The MFPs for Initial Price Applicability Year (IPAY) 2026 become effective under Medicare Part D on January 1, 2026. We believe it's essential that the value of treatments to patients be central to any determination of pricing, however, we don't see any evidence of that. While the DPNP evaluation process remains opaque, the evidence requirements to complete the DPNP Information Collection Request forms are rigorous and narrowly written. Companies must emphasize the value of their therapies with robust evidence from clinical trials and real-world studies. This evidence must highlight sustained benefits vs therapeutic alternatives identified by CMS to strengthen the value proposition to patients and Medicare. Read our full commentary at https://lnkd.in/gW_54SMp and contact us at https://lnkd.in/ebCSBH8b to discuss further.

Bluprint Oncology, Verascity Science, Cogency, and Blendworks are now all Powered by Petauri™. These 4 agencies, formerly part of the Brightly Network, comprise a comprehensive suite of medical communications agencies that specialize in oncology, hematology, and rare diseases across medical and commercial strategy, engagement, and education. These acquisitions continue to bolster Petauri's goal of ensuring scientific advancements reach patients with unmet medical needs. What kind of Petauri power does your brand need? Let’s discuss how we can apply our industry-leading innovation to the business challenges you’re facing. To learn more about our latest acquisitions please visit https://lnkd.in/erNRVKDC   #healthcare #HEOR #GlobalMarketAccess #EconomicModeling #HealthInnovation #medicalsaffairs #dataanalytics #healthcaredata #healthcareinnovation #medcomms #oncology, blend.works

Mtech Access-Powered by Petauri™ is excited to announce that early-bird pricing is now available for our upcoming Symposium. Attendees will gain insights into government healthcare policies and explore how to drive change in the NHS, transform pathways, and engage decision-makers. “The healthcare landscape is continuously evolving, and the need for effective collaboration between the NHS and industry partners has never been more critical. This year, our symposium is designed to address the common challenges faced in these partnerships and provide practical guidance for achieving successful outcomes.” – Jennie Smith, Director – NHS Insight & Interaction, Mtech Access. To see the full agenda and book your tickets, visit https://lnkd.in/eRVS7tNR. To discover other ways that Petauri can support your business, contact us at https://lnkd.in/ebCSBH8b

Per CMS, Part D plan sponsors are tasked with making formulary management decisions that are “based on scientific evidence, and may also be based on pharmacoeconomic considerations that achieve appropriate, safe, and cost-effective drug therapy.” Yet, there is no clarity in the Draft Guidance that the analyses CMS is undertaking for the DPNP are grounded in reproducible practices that could be made consistent with plan sponsor assessments or their decisions. We therefore provide several suggestions to improve clarity in the DPNP price-setting and negotiation processes. By not considering the multiple benefits of selected drugs in a manner that is transparent to all stakeholders, especially Part D plan sponsors, there is a high potential for disruptions to patient access to selected drugs. Although our recommendations cannot address some of the fundamental flaws of the IRA, they aim to improve CMS’s ongoing implementation of the law as expectations for transparency and consistency will increase post-Chevron. We encourage you to read our letter here https://lnkd.in/gX7zaq-v and contact us at https://lnkd.in/ebCSBH8b to discuss our comments further. #Healthcare #MarketAccess #CMS

Petauri™ is proud to share that The Kinetix Group-Powered by Petauri™ has been recognized as an MM+M Market Access Agency of the Year finalist! Now in its 21st year, the medical marketing industry’s premier awards program recognizes the campaigns, organizations, and people who created the year’s most compelling — and impactful — work. Kudos to the team for all their hard work and dedication. To learn more please visit https://lnkd.in/e9f3Jy4k or contact us directly at https://lnkd.in/eadTaaSM #healthcare #marketaccess #accessagencyoftheyear